DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20220170

Neonatal effects of maternal magnesium sulphate in preeclampsia: a case control study

Karunaa Joe Sengottaian, Sheela Shivamonga Rangappa

Abstract


Background: Preeclampsia is a significant public health problem in developed and developing countries. It is a multi-organ system disorder, hence making it demanding to find out severity markers.4 Awareness, recognition and knowledge of risk factors of preeclampsia will assist in predicting and lessen the recurrence of preeclampsia. In severe cases of preeclampsia and in eclampsia, magnesium sulfate is an effective anticonvulsant.Aims and objectives were: to document the clinical parameters of patients with or more than 28-week gestation having preeclampsia or eclampsia receiving magnesium sulphate and patients with or more than 28-week gestation having preeclampsia but not receiving magnesium sulphate; and to compare and study the obstetric and neonatal outcomes between the groups.

Methods: A case control study was performed among patients who delivered at RLJH hospital during study period (July 2020-July 2021), subjects who were administered magnesium sulphate due to maternal conditions were taken as cases and the subjects who did not receive magnesium sulphate were taken as controls. Obstetrical and neonatal outcomes were compared between both the groups. Data was entered in Microsoft excel sheet. Unpaired t test was performed. P value less than 0.0001 was considered significant.

Results: Magnesium sulphate did not have significant effects on the neonatal and obstetrical outcome.

Conclusions: The association between magnesium sulphate administration and neonatal outcomes were studied and it concludes that the administration of magnesium sulphate for the mother didn’t have significant effects on the neonatal and obstetrical outcome.


Keywords


Preeclampsia, Neonate, Magnesium sulphate, Eclampsia

Full Text:

PDF

References


Sibai BM. Hypertension in pregnancy. Clinical Obstet Gynecol. Am J Obstet Gynecol. 2004;190:1520.

World Health Organization. Make every mother and child count. Geneva: World health report. 2005. Available at: https://www.who.int/reproductivehealth /publications/maternal_perinatal_health/9241562900/en/. Accessed on 15 October 2021.

Khan KS, Wojdyla D, Say L, Gulmezoglu AM ,Van Look PF. WHO analysis of causes of maternal death: a systemic review. Lancet. 2006;367.

Hallak M, Berry SM, Madincea F, Romero R, Evans MI, Cotton DB. Fetal serum and amniotic fluid magnesium concentrations with maternal treatment. Obstet Gynecol. 1993;81:185-8.

Bain ES, Middleton PF, Crowther CA. Maternal adverse effects of different antenatal magnesium sulphate regimens for improving maternal and infant outcomes: a systematic review. BMC Pregnancy Childbirth. BioMed Central. 2013;13:195.

Bain E, Bubner T, Ashwood P. Implementation of a clinical practice guideline for antenatal magnesium sulphate for neuroprotection in Australia and New Zealand. Aust N Z J Obstet Gynaecol. 2013;53(1):86-9.

Pryde PG, Mittendorf R. Contemporary usage of obstetric magnesium sulfate: indication, contraindication, and relevance of dose. Obstet Gynecol. 2009;114:669-73.

Doyle LW, Crowther CA, Middleton P, Marret S, Rouse D . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev. 2009;1:CD004661.

Lyell DJ, Pullen K, Campbell L, Ching S, Druzin ML, Chitkara U, et al. Magnesium sulfate compared with nifedipine for acute tocolysis of preterm labor: a randomized controlled trial. Obstet Gynecol. 2007;110:61-7.

Lyell DJ, Penn A, Caughey A, Kogut E, McClellan L, Adams B, et al. Neonatal outcomes following antenatal magnesium sulfate exposure: follow up from a magnesium vs nifedipine tocolysis RCT. Am J Obstet Gynecol. 2009;201:180.

Greenberg MB, Penn AA, Thomas LJ, El-Sayed YY, Caughey AB, Lyell DJ. Neonatal medical admission in a term and late-preterm cohort exposed to magnesium sulfate. Am J Obstet Gynecol. 2011;204:515.

American College of Obstetricians and Gynecologists. Diagnosis and management of pre-eclampsia and eclampsia. ACOG Practice Bulletin No. 33. Obstet Gynecol. 2002;99:159-1.

Lucas MJ, Leveno KJ, Cunningham FG. A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia. N Engl J Med. 1995;333:201-5.

Coetzee EJ, Dommisse J, Anthony J. A randomised controlled trial of intravenous magnesium sulphate versus placebo in the management of women with severe pre-eclampsia. Br J Obstet Gynaecol. 1998;105:300-3.

Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J, et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet. 2002;359:1877-18.

Yilmaz Z, Yilmaz E, Kucukozkam T. Red blood cell distribution width: A simple parameter in preeclampsia. Pregnancy Hypertens. 2016;285-7.

Bain ES, Middleton PF, Crowther CA. Maternal adverse effects of different antenatal magnesium sulphate regimens for improving maternal and infant outcomes: a systematic review. BMC Pregnancy Childbirth. BioMed Central. 2013;13:195.

Bain E, Bubner T, Ashwood P. Implementation of a clinical practice guideline for antenatal magnesium sulphate for neuroprotection in Australia and New Zealand. Aust N Z J Obstet Gynaecol. 2013;53(1):86-9.

Nguyen TMN, Crowther CA, Wilkinson D. Magnesium sulphate for women at term for neuroprotection of the fetus. Cochrane Database Syst Rev. 2013;2:CD009395.

Drinkwater J. Magnesium sulphate for pre-eclampsia: care of the neonate. Pract Midwife. 2011;14(11):17-9.

Havranek T, Ashmeade TL, Afanador M et al. Effects of maternal magnesium sulfate administration on intestinal blood flow velocity in preterm neonates. Neonatology. 2011;100(1):44-9.

Bain ES, Middleton PF, Crowther CA. Maternal adverse effects of different antenatal magnesium sulphate regimens for improving maternal and infant outcomes: a systematic review. BMC Pregnancy Childbirth. BioMed Central. 2013;13:195.

Bain E, Bubner T, Ashwood P. Implementation of a clinical practice guideline for antenatal magnesium sulphate for neuro- protection in Australia and New Zealand. Aust N Z J Obstet Gynaecol. 2013;53(1):86-9.

Nguyen TM, Crowther CA, Wilkinson D, Bain E. Magnesium sulphate for women at term for neuroprotection of the fetus. Cochrane Database Syst Rev. 2013;2:CD009395.

Greenberg MB, Penn AA, Thomas LJ. Neonatal medical admission in a term and late-preterm cohort exposed to magne- sium sulfate. Am J Obstet Gynecol. 2011;204(6):515.

Greenberg MB, Penn AA, Whitaker KR. Effect of magne- sium sulfate exposure on term neonates. J Perinatol. 2013;33(3):188-93.

Sherwin CM, Balch A, Campbell SC, Fredrickson J, Clark EA, Varner M, Stockmann C, Korgenski EK, Bonkowsky JL, Spigarelli MG. Maternal magnesium sulphate exposure predicts neonatal magnesium blood concentrations. Basic Clin Pharmacol Toxicol. 2014;114(4):318-22.